论文部分内容阅读
This presentation will assess the current status of botanical new drug development,from the regulatory prospective of U.S.FDA.Regulatory environment for botanical drugs in the U.S.will be reviewed first with
This presentation will assess the current status of botanical new drug development, from the regulatory prospective of U.S. FDA. Regulatory environment for botanical drugs in the U.S. draft be first returned with